- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05172999
Loxenatide Plus LNG-IUS in Endometrial Atypical Hyperplasia
A Randomized Controlled Pilot Study of Polyethylene Glycol Loxenatide Plus LNG-IUS in Women With Endometrial Atypical Hyperplasia
Study Overview
Status
Intervention / Treatment
Detailed Description
Background: Obesity or overweight is associated with lower treatment response and longer time to achieve complete response(CR) in patients with atypical endometrial hyperplasia (AEH) who want to preserve fertility, as evidenced by our research and lots of published studies. The larger the baseline weight of AEH patients, the more the weight gains after high-dose progesterone treatment. Obese AEH patients have a lower response to high-dose progesterone.
Losing weight may help improve treatment response. Weight management and lifestyle intervention have been written into 2020 uterine NCCN (National Comprehensive Cancer Network) guidelines. Our research showed that metformin may improve insulin resistance in patients with AEH, and shorten time to achieve CR, and increase the CR rates. Theoretically, Losing weight can improve the chronic inflammatory environment in the endometrium and whole body and improve metabolic disorder which help patients achieve CR.
LNG-IUS will be adopted in this research. Though LNG-IUS and high-dose progesterone have similar efficacy in treating AEH patients, long-term treatment of progesterone has many side effects. Compared to oral progesterone, LNG-IUS has fewer side effects and fewer effects on weight gaining.
GLP-1 receptor agonist (GLP-1RA), which is one of the commonly used hypoglycemic drugs, has been approved for weight control. Loxenatide is the first Chinese-produced long-acting GLP-1R agonist. It is applicable for diabetes patients. In the USA, some GLP-1RA has been applied for losing weight, such as liraglutide and semaglutide. GLP-1RA acts through improving insulin sensitivity, decreasing glucagon secretion, inhibiting appetite, delaying gastric emptying, and improving whole-body inflammation condition. Loxenatide plus LNG-IUS may improve the efficacy of preserving fertility in obese AEH patients through help patients lose weight.
Objective: To investigate whether loxenatide plus LNG-IUS improves the efficacy of preserving fertility when compared to LNG-IUS alone in obese women with AEH who want fertility conservation.
Design: A pilot prospective randomized controlled study is designed. And this study is open-label. We use SPSS software (version 22.0, IBM) to perform simple randomization and get randomized numbers. And participants will be randomly assigned (1:1) to receive LNG-IUS alone or loxenatide plus LNG-IUS. Patients in LNG-IUS alone group will accept LNG-IUS insertion as treatment and the other group cases will be treated with loxneatide plus LNG-IUS.
All enrolled patients will receive basic medical treatment in weight management and lifestyle improvement support, no enhanced interventions. Hysteroscopic assessment, metabolic and inflammatory indications will be performed every 12-16 weeks, while other indexes (weight, body composition change, side effects, and so on) will be evaluated every month.
For the efficacy evaluation, CR is defined as the reversion of endometrial atypical hyperplasia to proliferative or secretory endometrium; partial response (PR) is defined as regression to simple or complex hyperplasia without atypia; no response (NR) is defined as the persistence of the disease, and progressive disease (PD) is defined as the appearance of endometrial cancer in patients. Continuous therapies will be needed in PR, NR, or PD. Two months of maintenance treatment will be recommended for patients with CR, and participants will be followed up for 2 years.
Outcomes: Primary outcome is the CR rates of the two groups (LNG-IUS alone verse LNG-IUS+ loxenatide) in 16-week. Secondary outcomes include CR rates in 32 weeks, assessment of ovarian functions, improvement of weight, insulin resistance, chronic inflammation condition, and time to achieve CR, and safety and side events during the therapy, and the recurrence rates, pregnancy rates, and live birth rates in two years.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
- Name: XIAOJUN CHEN, PhD
- Phone Number: 86-021-33189900
- Email: cxjlhjj@163.com
Study Contact Backup
- Name: WEIWEI SHAN, PhD
- Phone Number: 8613817813106
- Email: fdsww1024@sina.cn
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200090
- Recruiting
- Obstetrics & Gynecology Hospital of Fudan University
-
Contact:
- WEIWEI SHAN, PhD
- Phone Number: 086-13817813106
- Email: fdsww1024@sina.cn
-
Contact:
- DANDAN JU
- Phone Number: 021-33189900-8408
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- BMI (body mass index) ≥28kg/m2
- Consent informed and signed
- Pathologically confirmed as endometrial atypical hyperplasia
- Have a strong desire to reproduce and ask for fertility preservation or those who insist on keeping the uterus despite no reproductive requirements
- Have good compliance and follow-up conditions, and patients are willing to follow up in Obstetrics and Gynecology Hospital of Fudan University in time
Exclusion Criteria:
- Diagnosed as type 2 diabetes
- Diabetic ketoacidosis
- History of acute pancreatitis
- Have a history or family history of medullary thyroid carcinoma; multiple endocrine neoplasia syndrome type 2 (MEN2)
- Combined with severe medical disease or severely impaired liver and kidney function
- Patients with other types of endometrial cancer or other malignant tumors of the reproductive system; patients with breast cancer or other hormone- dependent tumors that cannot be used with progesterone
- Those who require hysterectomy or other methods other than conservative treatment with drugs
- Known or suspected pregnancy
- Currently suffering from pelvic inflammatory disease or diagnosed as pelvic inflammatory disease
- Lower reproductive system infection
- abnormal cervical dysplasia
- Congenital or acquired uterine abnormalities, including fibroids that deform the uterine cavity
- Allergic to any parts of LNG-IUS components
- The uterine cavity is too large (average diameter is over 7cm) or the history of LNG-IUS falling off
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: LNG-IUS
enrolled patients will receive LNG-IUS for 6 months or longer till complete response
|
Enrolled patients will be inserted this device for treating AEH to preserve fertility for 3-6 months or longer till complete response or operation if treatment fails, and the device may be removed if treatment changes.
Other Names:
|
Experimental: LOX+LNG-IUS
enrolled patients will receive LNG-IUS plus polyethylene glycol loxenatide for treatment.
|
Enrolled patients will be inserted this device for treating AEH to preserve fertility for 3-6 months or longer till complete response or operation if treatment fails, and the device may be removed if treatment changes.
Other Names:
Initiate injection of Loxenatide will be 0.1mg per week, if the patient can tolerate, the dose will be increased to 0.2mg per week, or else 0.1mg per week will be injected and the injection will last for no more than 28 weeks.
If the patient cannot tolerate the least 0.1mg/week, she must be excluded from this trial.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pathological complete response (CR) rates
Time Frame: From date of randomization until the date of CR, assessed up to 16 weeks.
|
The 16-week CR rates will be calculated in two groups
|
From date of randomization until the date of CR, assessed up to 16 weeks.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
32-week complete response (CR) rates
Time Frame: From date of randomization until the date of CR, assessed up to 32 weeks.
|
The 32-week complete response rates will be calculated in two groups
|
From date of randomization until the date of CR, assessed up to 32 weeks.
|
weight change
Time Frame: From date of randomization until the date of CR, assessed up to 32weeks.
|
weight change in 32-week's intervention, weight will be recorded every month
|
From date of randomization until the date of CR, assessed up to 32weeks.
|
changing of insulin resistance
Time Frame: From date of randomization until the date of CR, assessed up to 32weeks.
|
indicators of insulin resistance will be assessed at baseline and every 12-16 weeks.
|
From date of randomization until the date of CR, assessed up to 32weeks.
|
change of chronic inflammation status
Time Frame: From date of randomization until the date of CR, assessed up to 32 weeks.
|
Change of chronic inflammation indications (tumor necrosis factor (TNF-α), interleukin-1(IL-1), interleukin-6 (IL-6)) in 32 weeks
|
From date of randomization until the date of CR, assessed up to 32 weeks.
|
change of ovarian functions
Time Frame: From date of randomization until 6 months after treatment is over
|
AMH (anti-mullerian hormone ) will be assessed at baseline and every 12-16 weeks
|
From date of randomization until 6 months after treatment is over
|
Time of pathological complete response (CR)
Time Frame: From date of randomization until the date of CR, assessed up to 2 years
|
Time of histologic regression from AEH to proliferative or secretory endometrium
|
From date of randomization until the date of CR, assessed up to 2 years
|
safety and side effects
Time Frame: From date of randomization until the date of CR, assessed up to 2 years
|
Adverse events related with Liraglutide and LNG-IUS.
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 will be recorded, as well as incidence of adverse events.
|
From date of randomization until the date of CR, assessed up to 2 years
|
Relapse rates
Time Frame: up to 2 years after the treatment for each patient
|
All enrolled patients will be followed up for 2 years.
During the following-up period, if patients recur after complete regression, they will be counted and the number of recurrence will be divided by number of patients followed up, then we can get the relapse rates.Comparison will be performed between two groups.
|
up to 2 years after the treatment for each patient
|
pregnancy outcomes
Time Frame: up to 2 years after the treatment for each patient
|
For patients have a desire for fertility, pregnancies, births and related outcomes will be counted, and the rate of pregnancy will be counted as number of pregnancies/ number of patients trying to fertility in the following period.
Comparison will be performed between two groups
|
up to 2 years after the treatment for each patient
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: XIAOJUN CHEN, PhD, Obstetrics & Gynecology Hospital of Fudan University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Uterine Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Infertility
- Hyperplasia
- Endometrial Hyperplasia
- Physiological Effects of Drugs
- Contraceptive Agents, Hormonal
- Contraceptive Agents
- Reproductive Control Agents
- Contraceptives, Oral
- Contraceptive Agents, Female
- Contraceptives, Oral, Synthetic
- Levonorgestrel
Other Study ID Numbers
- 53211033
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
Fundació Sant Joan de DéuRecruitingObesity, Childhood | Obesity, AdolescentSpain
-
Consorcio Centro de Investigación Biomédica en...Maimónides Biomedical Research Institute of Córdoba; Instituto de Salud Carlos... and other collaboratorsActive, not recruiting
-
University of HoustonBaylor College of MedicineCompleted
Clinical Trials on levonorgestrel-releasing intrauterine system
-
University of North Carolina, Chapel HillSociety of Family PlanningCompletedPostpartum ContraceptionUnited States
-
Assiut UniversityTerminated
-
Sebela Women's Health Inc.Synteract, Inc.Completed
-
Peking Union Medical College HospitalCompleted
-
University of LouisvilleTerminatedContraceptionUnited States
-
University of ChicagoTerminated
-
University of Campinas, BrazilCompleted
-
Gaziosmanpasa Research and Education HospitalCompletedPelvic Pain | Isthmocele | Post-menstrual Spotting BleedingTurkey
-
National Institute of Allergy and Infectious Diseases...CompletedHIV InfectionsUnited States, Puerto Rico
-
University of OklahomaCompleted